Sinovac Biotech (SVA) director Jiao Shuge files initial Form 3

Rhea-AI Filing Summary

SINOVAC BIOTECH LTD director Jiao Shuge has filed an initial ownership report on Form 3. This filing identifies him as a director of the company and establishes his status as an insider. The filing does not report any share purchases, sales, or other transactions.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

JIAO SHUGE

(Last) (First) (Middle)

25/F, FFC, 5 DONG SAN HUAN CENTRAL ROAD

CHAOYANG DISTRICT

(Street)

BEIJING 100020

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SINOVAC BIOTECH LTD [ SVA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Jia Zhao, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the SINOVAC BIOTECH LTD (SVA) Form 3 filing report?

The Form 3 filing reports that Jiao Shuge is an insider of SINOVAC BIOTECH LTD as a director. It is an initial statement of beneficial ownership and does not list any specific share transactions or changes in holdings.

Who is the reporting person in SINOVAC BIOTECH LTD (SVA) Form 3?

The reporting person is Jiao Shuge, identified as a director of SINOVAC BIOTECH LTD. The Form 3 formally records his insider status with the SEC but does not include any purchase, sale, or derivative transactions in this filing.

Does the SINOVAC BIOTECH LTD (SVA) Form 3 show any insider buy or sell transactions?

No, this Form 3 shows no buy or sell transactions. The transaction summary lists zero purchases, zero sales, and no derivative exercises, gifts, tax withholdings, or restructurings, indicating only an initial ownership reporting event.

What is the purpose of a Form 3 for SINOVAC BIOTECH LTD (SVA)?

Form 3 serves as an initial statement of beneficial ownership when someone becomes an insider, such as a director. For SINOVAC BIOTECH LTD, it records Jiao Shuge’s insider status without detailing any trades or changes in share ownership in this filing.

Are there any derivative securities reported in the SINOVAC BIOTECH LTD (SVA) Form 3?

No derivative securities are reported in this Form 3. The derivative summary is empty and derivativeTransactionCount is zero, indicating no options, warrants, or other derivative positions disclosed for director Jiao Shuge in this specific filing.